

## Supplemental Online Content

Joly P, Lafon A, Houivet E, et al. Efficacy of methotrexate alone vs methotrexate plus low-dose prednisone in patients with alopecia areata totalis or universalis: a 2-step double-blind randomized clinical trial. *JAMA Dermatol*. Published online March 8, 2023. doi:10.1001/jamadermatol.2022.6687

**eAppendix.** Exclusion criteria

**eTable.** QOL of responders (patients who achieved complete/almost complete HR (< SALT 10) versus patients who did not

This supplemental material has been provided by the authors to give readers additional information about their work.

## **eAppendix. Exclusion criteria**

- pregnant or breast feeding woman
- Known hyper sensitivity to methotrexate or prednisone
- HIV infection
- active hepatitis B or C infection
- previous treatment with conventional immunosuppressant (cyclosporine, mycophenolate mofetil, cyclophosphamide, azathioprine, méthotrexate) or any other treatment which may be effective in AA during the 2 months before the start of the study
- severe cardiac arrhythmia
- severe cardiac insufficiency (class III or IV, NYHA)
- unstable angina pectoris or ischemic cardiopathy ( recent myocardial infarction)
- active liver disease ( excluding liver steatosis) or past history of severe liver disease
- chronic intake of drugs with a known liver toxicity
- chronic alcohol consumption (>60 g/day)
- severe chronic renal insufficiency (creatinine clearance < 50 ml/min according to Cockcroft formula),
- severe diabetes mellitus (glycemia  $\geq 2,5\text{g/L}$  and/or HbA1C  $\geq 8.5\%$ )
- recent gastric ulcer ,
- any other concomitant disease which may need a systemic corticosteroid treatment at a dose  $>0.3 \text{ mg/Kg/day}$
- severe arterial hypertension
- severe bacterial infection which have needed an hospitalization for IV infusion of antibiotics during the 4 months before study entry
- past history of severe infection (necrotizing, osteomyelitis, septic arthritis...) during the 12 months before study entry
- concomitant neoplasia ( except basal cell carcinoma and intra epithelial SCC )
- past-history of neoplasia during the 5 years before study entry
- non compliant patient,
- inherited or acquired immunodeficiency
- administration of a live vaccine within four weeks before the study
- patients who have already been treated with methotrexate or oral prednisone / prednisolone for their AA .
- Karnofsky index < à 50 %
- severe chronic obstructive bronchial disease (VEMS < 50 %) or dyspnea grade III),
- severe psychiatric disorders ,

- symptomatic osteoporosis
- blood cytopenia (hemoglobin < 10 g/l and / or leucocytes < 3000/mm<sup>3</sup> and : or platelets < 100 000/mm<sup>3</sup>),
- serum albumin level < 25 g/l,

**eTable. QOL of responders (patients who achieved complete/almost complete HR (< SALT 10) versus patients who did not**

	Baseline			Month 12		
	Non responders (n=49)	Responders (n=8)	p	Non responders (n=49)	Responders (n=8)	p
<b>DLQI</b>			0.37			0.05
n	49	8		47	8	
mean ± SD	7.8 ± 6.6	5.6 ± 4.7		7.4 ± 7.1	2.4 ± 2.3	
<b>SKINDEX TOTAL</b>			0.62			<b>0.03*</b>
n	49	8		47	8	
mean ± SD	107.4 ± 60.2	96.7 ± 30		108.2 ± 67.9	53.4 ± 37.5	
<b>SCALPDEX TOTAL</b>			0.97			<b>0.03*</b>
n	49	8		47	8	
mean ± SD	128.2 ± 55.4	127.5 ± 30.3		130.6 ± 62.5	79.4 ± 39.5	

\* : p< 0.05 with Student's t-test